Clinical Trial Update: Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic study evaluating adding aprepitant to cisplatin-etoposide in cancer patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumor

Drugs mentioned

• Aprepitant (aprepitant)
• CISPLATIN (cisplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Tumor | Phase 4 | Status: TERMINATED